SCHEMBL4239405

SCHEMBL4239405

FC(F)(F)COc1cccc(-c2nc3ncc(-c4ccco4)cc3[nH]2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRA4 P48169 1/20 0.43
GABRA6 Q16445 1/20 0.43
AURKA O14965 5/20 0.42
IKBKE Q14164 5/20 0.41
TBK1 Q9UHD2 5/20 0.41
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
PRMT5 O14744 1/20 0.35
ADORA1 P30542 1/20 0.35
LCLAT1 Q6UWP7 2/20 0.35
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054895 0.90 AURKA (0.44) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL4230420 0.87 AURKA (0.46) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL4054953 0.86 FGFR1 (0.49) AURKAIKBKETBK1NOS3NOS1
SCHEMBL4055581 0.85 CYP1A2 (0.47) AURKABRAF
SCHEMBL4060694 0.84 AURKA (0.45) AURKAIKBKETBK1NOS3NOS1
SCHEMBL4055195 0.84 AURKA (0.60) AURKAIKBKETBK1NOS3NOS1
SCHEMBL4058710 0.84 TBK1 (0.45) AURKAIKBKETBK1FGFR1FGFR2
SCHEMBL13608615 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL4055260 0.84 AURKA (0.47) AURKAIKBKETBK1NOS3NOS1
SCHEMBL4052283 0.83 DHODH (0.47) AURKAIKBKETBK1NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B GABRA1 3371/4885GABRG2 3462/4885GABRB3 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.